BIRC5 and pancreatic neoplasm: In particular, the hTERT antigen epitope of pancreatic cancer cells, in combination with survivin (SRV.A2) and carcinoembryonic antigen (CEA), can bind to the HLA-A2 on the surface of dendritic cells, forming the antigen peptide-MHC class II complexes in antigen-presenting cells, which in turn trigger cytotoxic CD8+ T lymphocytes that specifically target pancreatic cancer cells in an hTERT-dependent manner [271].